Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Dangal TV Channel Ranked No.1 on YouTube Globally as per Tubular Leaderboard in Media & Entertainment and Films & Movies Categories
Dangal TV, one of India’s leading entertainment brands, has set yet another…
Eightco Holdings Inc. ($ORBS) Digital Asset Treasury Launches “Chairman’s Message” Video Series
Reinforces "Power of Eight" Initiative, targeting 800M Worldcoin (WLD) tokens and verify…
Kia PV5 Redefines Mobility ThroughCustomerCentric Modular Design
Built to meet customers’ evolving needs, PV5 is first dedicated model in…
Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2025
September 26, 2025 16:04 ET Â | Source: Maris-Tech Ltd. The company continues…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET Â | Source: C4 Therapeutics, Inc. Cemsidomide in…
IOC welcomes three new directors
08 September 2025 -Â The International Olympic Committee (IOC) has announced the appointment…
IOC Executive Board meeting 18 and 19 September 2025 Information for the media
05 September 2025 - The International Olympic Committee (IOC) Executive Board (EB) will hold a…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
41/2025Trifork Group: Interim report for the quarter and half-year ending 30 June 2025
Company announcement no. 41/2025Schindellegi, Switzerland – 19 August 2025 Interim Financial Report…